Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

HeartMate 3 LVAD

With Full Maglev Flow Technology

MOMENTUM 3 & UNOS

MOMENTUM 3 and UNOS registry propensity-matched comparison

Comparative analysis between HeartMate 3 Left Ventricular Assist Device (LVAD) and heart transplantation (HTx) in heart failure patients under 50, using data from the MOMENTUM 3 trial and the UNOS registry.

View 2025 ESC-HFA Presentation


In advanced heart failure patients <50, 2-year outcomes showed:
 

91% 2-Year Survival

From time of implant or transplantation, HeartMate 3 LVAD and HTx patients have equivalent survival of 91%.
 

12% Decreased Risk of Death

From time of implant or HTx listing, HeartMate 3 LVAD patients have a 12% decreased risk of death compared to risk of death or delisting* for HTx candidates.
 


*delisted for worsening health

MAT-2506017 v3.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2025 Abbott. All Rights Reserved.

MAT-1900882 v15.0